In the SURMOUNT-1 clinical trial, patients without diabetes lost an average of 15-21% of baseline body weight over 72 weeks, depending on dosage, with somewhat lower averages observed in patients with type 2 diabetes in SURMOUNT-2
Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence Obesity Reviews, 2026
We have previously observed that GLP-1RA and SGLT-2i prescriptions are being initiated increasingly by general practitioners in addition to hospital-based physicians
Potential indirect causes include hypoglycemia or blood sugar fluctuations, gastrointestinal distress (nausea, vomiting), significant caloric restriction, sleep disruption, or pre-existing mood conditions
The products are scheduled to roll out nationwide at Walmart and CVS locations this spring